Clinical Trial Detail

NCT ID NCT02893930
Title Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

pancreatic endocrine carcinoma

Therapies

Sapanisertib

Age Groups: senior adult

No variant requirements are available.